No Reverse Split anything soon imoif they need money (and they will) it’s logical to first draw from the Thomvest loan agreement, then do a shelf offering to raise any more needed capital.
a reverse split after FDA Ryplazim marketing approval, around 5:1 imo.
optimal time would be to wait to do the reverse split until after 4050 marketing approval in the U.K. for Alstrom patients under their Early Access Program (eoy 2019 to mid 2020 imo).
any NASDAQ move PRIOR to any FDA drug approval news would be meaningless, no houses would invest.